


I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being transmitted via the Office electronic filing system in accordance with § 1.6(a)(4).

Dated: May 22, 2008

Signature: 
(Heather R. Kissling)

Docket No.: 30187/41217
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Martin Kintrup et al.

Application No.: 10/533,618

Confirmation No.: 1749

Filed: February 6, 2006

Art Unit: 1645

For: MEANS AND METHODS FOR DIAGNOSING
A TREPONEMA INFECTION

Examiner: B. J. Gangle

SUPPLEMENTAL RESPONSE TO NON-FINAL OFFICE ACTION

MS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

This paper is submitted in further response to the Office Action dated January 3, 2008. Applicants' Response to Non-Final Office Action filed on May 5, 2008, referenced two figures, Appendix Page 1 and Appendix Page 2. The figures were erroneously identical. Submitted herewith are replacement figures labeled as "Corrected Appendix Page 1" and "Corrected Appendix Page 2." Corrected Appendix Page 2 is identical to the originally submitted Appendix Page 2, and is provided herewith merely for the convenience of the Office. Applicants respectfully request that the Office consider Corrected Appendix Page 1 and Corrected Appendix Page 2 with the Response to Non-Final Office Action submitted May 5, 2008.

The figures were discussed in the Response to Non-Final Office Action submitted May 5, 2008, on page 13. Briefly, Corrected Appendix Page 1 shows a test strip employing VDRL and Treponema-specific antigens in which an ordinary buffer system for immunoassays is employed (0.05% TWEEN). VDRL bands were not detectable under reaction conditions suitable for Treponema antigens. Corrected Appendix Page 2 shows a

test strip employing VDRL and Treponema-specific antigens developed using 0.001% TWEEN (i.e., a 50-fold reduction in TWEEN concentration compared to the conditions resulting in Corrected Appendix Page 1). VDRL bands were detectable under these conditions.

This Supplemental Response is intended to correct an error in the Response to Non-Final Office Action filed on May 5, 2008, for which a one-month extension of time fee was timely submitted. Accordingly, no fees are believed to be due. However, the Director is hereby authorized to charge any deficiency in the extension or fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 13-2855, under Order No. 30187/41217. If further extension of time is required, please consider this to be a request for further extension.

Dated: May 22, 2008

Respectfully submitted,

By 
Heather R. Kissling

Registration No.: 45,790
MARSHALL, GERSTEIN & BORUN LLP
233 S. Wacker Drive, Suite 6300
Sears Tower
Chicago, Illinois 60606-6357
(312) 474-6300
Attorney for Applicant